Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)

Table 4 Univariate analysis of risk factors for chronic graft-versus-host disease

Variable	N	cGVHD			Extensive cGVHD
		HR	95% CI	P	HR	95% CI	P
Age for recipients, years
<40	286	1.00			1.00
≥40	180	1.34	1.06-1.70	0.016	1.54	1.12-2.11	0.007
Age for donor, years
<40	288	1.00			1.00
≥40	178	1.10	0.848-1.43	0.473	1.362	0.971-1.912	0.074
Age for donor and recipients, years
recipients < 40 and donor < 40	243	1.00			1.00
recipients < 40 and donor ≥ 40	52	0.72	0.46-1.15	0.174	0.90	0.49-1.64	0.729
recipients ≥ 40 and donor < 40	47	1.24	0.82-1.88	0.314	1.46	0.84-2.53	0.179
recipients ≥ 40 and donor ≥ 40	124	1.38	1.03-1.85	0.034	1.76	1.20-2.59	0.004
Donor-recipient gender
Other	336	1.00			1.00
Female → Male	130	1.48	1.15-1.90	0.002	1.92	1.39-2.65	0.000
Stem cell source
BM + PB	241	1.00			1.00
PB	225	0.51	0.40-0.65	0.000	0.30	0.21-0.43	0.000
Leukemia type
AL	287	1.00			1.00
CML	145	1.04	0.80-1.34	0.778	0.94	0.66-1.35	0.747
Conditioning regimen
BuCy	326	1.00			1.00
TBICy	23	0.66	0.34-1.29	0.226	0.56	0.21-1.54	0.264
BuFlu	116	1.49	1.15-1.94	0.003	1.96	1.41-2.73	0.000
Donor-recipient blood type
Match	273	1.00			1.00
Mis-match	193	1.14	0.89-1.45	0.301	1.18	0.85-1.60	0.317
Disease Stage
Non-advanced	415	1.00			1.00
Advanced	51	1.19	0.80-1.78	0.389	0.96	0.54-1.70	0.890
aGVHD
No	332	1.00			1.00
Yes	134	1.82	1.42-2.34	0.000	2.14	1.55-2.96	0.000

aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; BM, bone marrow; BP, peripheral blood; AL, acute leukemia; CML, chronic myelogenous leukemia; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; MMF, mycophenolate mofetil; Flu, fludarabin; Non-advanced stage, including acute leukemia(AL) in CR,CML in CP and AP, MDS-RAEB; Advanced stage, including AL in NR and CML in BC.

ISSN: 1756-8722